Issues surrounding the health economic evaluation of genomic technologies.

ABSTRACT:

Aim

Genomic interventions could enable improved disease stratification and individually tailored therapies. However, they have had a limited impact on clinical practice to date due to a lack of evidence, particularly economic evidence. This is partly because health economists are yet to reach consensus on whether existing methods are sufficient to evaluate genomic technologies. As different approaches may produce conflicting adoption decisions, clarification is urgently required. This article summarizes the methodological issues associated with conducting economic evaluations of genomic interventions.

Materials & methods

A structured literature review was conducted to identify references that considered the methodological challenges faced when conducting economic evaluations

SUBMITTER: Buchanan J 

PROVIDER: S-EPMC3909837 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature